PolySciTech (
www.polyscitech.com)
provides a wide array of maleimide-PEG-PLA and mPEG-PLA block copolymers for
forming nanoparticles. Recently these types of polymers were used as precursors
to generate paclitaxel loaded nanoparticles decorated with extra domain B
aptamer for targeting towards glioma cells for brain cancer therapy. Read more:
Gu, Guangzhi, Quanyin Hu, Xingye Feng, Xiaoling Gao, Jiang Menglin, Ting Kang,
Di Jiang, Qingxiang Song, Hongzhuan Chen, and Jun Chen. "PEG-PLA
nanoparticles modified with APT-EDB peptide for enhanced anti-angiogenic and
anti-glioma therapy." Biomaterials (2014). http://www.sciencedirect.com/science/article/pii/S014296121400698X
“Abstract: Tumor neovasculature and tumor cells
dual-targeting chemotherapy can not only destroy the tumor neovasculature, cut
off the supply of nutrition and starve the tumor cells, but also directly kill
tumor cells, holding great potential in overcoming the drawbacks of
anti-angiogenic therapy only and improving the anti-glioma efficacy. In the
present study, by taking advantage of the specific expression of fibronectin
extra domain B (EDB) on both glioma neovasculature endothelial cells and glioma
cells, we constructed EDB-targeted peptide APTEDB-modified PEG-PLA
nanoparticles (APT-NP) for paclitaxel (PTX) loading to enable tumor
neovasculature and tumor cells dual-targeting chemotherapy. PTX-loaded APT-NP
showed satisfactory encapsulated efficiency, loading capacity and size
distribution. In human umbilical vein endothelial cells, APT-NP exhibited
significantly elevated cellular accumulation via energy-dependent, caveolae and
lipid raft-involved endocytosis, and improved PTX-induced apoptosis therein.
Both in vitro tube formation assay and in vivo matrigel angiogenesis analysis
confirmed that APT-NP significantly improved the antiangiogenic ability of PTX.
In U87MG cells, APT-NP showed elevated cellular internalization and also
enhanced the cytotoxicity of the loaded PTX. Following intravenous
administration, as shown by both in vivo live animal imaging and tissue
distribution analysis, APT-NP achieved a much higher and specific accumulation
within the glioma. As a result, APT-NP-PTX exhibited improved anti-glioma
efficacy over unmodified nanoparticles and Taxol® in both subcutaneous and
intracranial U87MG xenograft models. These findings collectively indicated that
APTEDB-modified nanoparticles might serve as a promising nanocarrier for tumor
cells and neovasculature dual-targeting chemotherapy and hold great potential
in improving the efficacy anti-glioma therapy. Keywords: Nanoparticles; APTEDB
peptide; Dual-targeting; Paclitaxel; Glioma therapy”
No comments:
Post a Comment